移动通信网 程然
在旧金山一间手术室里,一位外科医生正坐在显示器前,操控手柄来自一台 Xbox 游戏机。6 米之外,一根细软的导管正沿着模拟血管缓缓推进,屏幕上的实时 X 光影像记录着它的每一步移动。这不是游戏演示,而是 Remedy Robotics 公司 N1 手术机器人的日常测试场景。这家总部位于旧金山的初创公司,正在尝试用远程手术机器人解决一个长期困扰全球医疗体系的难题——让偏远地区的卒中患者在黄金时间窗内获得取栓治疗。
为什么远程手术从卒中切入
卒中救治曾长期笼罩在“治疗虚无主义”的阴影之下。早在 1991 年,两位神经科医生在社论中悲观地写道,希望卒中药物疗法能“逆转虚无主义的趋势”。五年后,溶栓药物改变了局面;大约十年后,机械取栓术问世——医生通过物理方式将血栓从动脉中取出,卒中从“致残或死亡的判决”变成可治疗的急症。
然而三十年过去,取栓手术本质上仍是一场“盲探”。医生站在患者身旁,从腹股沟的小切口送入导丝,再沿导丝推入导管,在只有 X 光平面影像、看不见软组织血管的条件下,一寸一寸向上推进。更棘手的是操控逻辑并不直观:导丝在体内可能发生扭转,医生想向左转时,导丝尖端实际上可能转向右侧。每一次转弯都依赖经验与手感。
【关键数据】
- 全球缺血性卒中患者: 每年至少 500 万人(2025 年数据)
- 取栓手术可及率: 目前仅约 1/10 的 eligible 患者获得治疗(行业核心痛点)
- 美国卒中致死排名: 第四大死亡原因
- N1 机器人驱动模块: 导管输送轨道集成 7 个模块
- 远程操控范围: 可支持数公里外的异地操作

工程师思维重构手术范式
N1 机器人的技术方案颇具巧思:导管沿一条内置 7 个模块的轨道输送,通过一根细金属丝实现精确驱动,医生即使身处数公里之外,也能精确控制导管在血管系统中的行进。联合创始人 Jake Sganga 负责技术侧,他的搭档、澳大利亚裔临床医生 David Bell 此前接受过心脏外科训练。两人的分工恰好覆盖了这项技术最难跨越的两端——工程能力与临床判断。
Bell 对产品的评价标准颇为冷峻。当体验者称赞设备“操作更平滑、更精确”时,他直接纠正:“平滑和精确不是临床结局,医生的人体工学也不是。”在他看来,唯一重要的指标是:这台机器人能否让原本无法及时获得取栓治疗的患者得到救治。目前全球仅有约十分之一符合条件的患者真正接受了取栓手术,大量偏远地区患者在转院途中损失了关键的治疗时间窗——每延误一分钟,数以百万计的脑细胞就会因缺血而肿胀、死亡。
“我们希望它有点像电子游戏,操作起来轻松一些,”Bell 说,“但我们不希望它被去人性化,仿佛只是又一次‘游戏结束’。”这种平衡感贯穿整个产品设计:降低操作门槛是为了让远程医生更快上手,而非淡化医疗行为的严肃性。事实上,Remedy 已经迈出第一步,在一小组患者身上完成了远程系统测试。
从样机到普及:三道待解关卡
“远程卒中的需求是公认的,这只是一个很难啃的难题。”Sganga 的表态点出了行业的普遍困境。让远程手术真正嵌入卒中救治体系,仅靠一台可靠的机器人远远不够。Sganga 坦言,落地取决于三个层面:通信基础设施能否提供足够低时延、高可靠的连接;医院端的资源调配与工作流程能否适配异地手术模式;以及最终能否拿出扎实的临床证据,证明患者确实从中获益。
第三个条件尤为关键。远程手术此前数十年被反复讨论却始终未成气候,核心障碍正是缺乏大规模、可复现的临床获益数据。Remedy 的小规模远程测试只是起点,后续还需通过监管审批、扩大试验规模、验证网络异常场景下的安全冗余设计。对于一家初创公司而言,这条路径的资金和时间成本都不容低估。
从更宏观的视角看,远程手术机器人与 5G/6G 通信技术的演进正在形成共振。超低时延传输、网络切片保障、边缘计算协同——这些通信产业持续投入的能力,恰是远程手术从“可行演示”走向“常规临床”的底层支撑。如果 Remedy 及其同类公司能够跑通商业模式,偏远医院部署机器人、城市专家远程执刀的分工体系或将重塑全球急救医疗资源的分配格局。在那之前,每一例成功的远程取栓,都是在为这个尚未兑现的承诺积累信任。
出处:Can Robots Bring Stroke Surgery to Remote Hospitals?
英文原文I am practicing brain surgery on a patient lying 6 meters away, out of my sight and reach. I press a foot pedal, activating the controller in my hand, and carefully steer a thin flexible tube called a catheter up through the patient’s blood vessels. I head for what I believe to be the brain, tracking my progress on the live X-ray feed. As I imagine finding a blood clot, David Bell , the surgeon seated to my right, helpfully reminds me that every minute a stroke goes untreated, millions of brain cells suffocate, swell, and die . The patient under the X-ray in Bell’s office is not flesh and blood, but a plastic container holding long branches of silicone tubing. The controller I hold comes from an Xbox. But the surgical robot is real. The Remedy N1 is designed for emergency operations, including thrombectomies , the standard brain operation for acute ischemic strokes caused by blood clots. Ischemia, a restriction of blood flow, is the most common cause of stroke. “We want it to feel a bit like a video game—a bit easy,” Bell says. “But we don’t want to dehumanize it as if there’s just another ‘game over.’ ” Bell, a clinician and former cardiac-surgery trainee from Australia, cofounded Remedy Robotics , based in San Francisco. With a team of engineers, he developed this robotic catheter and its related software to help ischemic stroke patients in remote and rural places, who lose crucial hours while being transferred away from hospitals incapable of providing care. According to 2025 data, at least 5 million people around the world suffer ischemic strokes every year. In the United States, stroke is the fourth leading cause of death. When Remedy Robotics cofounders Jake Sganga [left] and David Bell initially met, they matched each other’s energy right away. Christie Hemm Klok The screen shows my catheter at a fork in the narrowing road, and I decide to take a sharp right; I think I can make it. This device feels easier to drive than a typical robotic instrument that I controlled on a hospital tour the summer prior. I say to Bell that here my movements are smoother, more precise—exactly the talking point you’d expect to hear from a surgical robotics company. Never mind that, Bell corrects me: “Smoothness and precision are not clinical outcomes. Neither is a surgeon’s ergonomics.” For Bell, the outcome that matters is whether the robot can get stroke treatment to patients who otherwise wouldn’t receive it in time. Today, only about 1 in 10 patients eligible for thrombectomy receive one. That’s where the long-unrealized promise of telesurgery is meeting an urgent problem: providing access to thrombectomies before life-threatening damage takes hold. But can putting a robot in one hospital and a surgeon somewhere else actually close that gap? Remedy has already taken a first step, remotely testing its system on a small group of patients. “The remote stroke need is well known,” says Jake Sganga , who cofounded Remedy with Bell and leads the technology side. “It’s just a hard problem to take on.” Making telesurgery a practical part of stroke care will require more than a capable robot: It will depend on communications infrastructure, hospital resources and workflows, and ultimately, evidence that patients actually benefit. Why Telesurgery Starts With Stroke As recently as the early ’90s , physicians who treated stroke struggled with “ therapeutic nihilism .” A 1991 editorial by two lamenting neurologists expressed hope that a successful drug therapy for stroke would emerge that would “reverse the trend of nihilism.” Five years later, clot-busting drugs revolutionized stroke treatment, followed about a decade later by mechanical thrombectomy, in which a blood clot is physically removed from an artery . In a standard thrombectomy a surgeon snakes a flexible wire through a small opening in the patient’s groin. This guide wire sets the route for a fine hollow tube around it, the catheter, to travel through the blood vessels to the brain, where instruments remove the clot. Suddenly a stroke was no longer a sentence of profound disability or death but a treatable event. Yet decades later, thrombectomies remain inherently blind expeditions. The surgeon stands beside the patient, physically pushing these lines up, inch by inch. The only view comes from a live X-ray, which can’t see soft tissues like blood vessels. The surgeon shoots brief puffs of contrast dye through the catheter to illuminate the path ahead. A nimble operator can avoid scraping or piercing artery walls while bending the guide wire’s rounded tip around corners. But even these left or right turns are not intuitive. The guide wire can twist inside the body, and because the surgeon sees only a flat silhouette, steering it left may actually rotate the guidewire to the right. The N1 robot feeds the catheter along a rail lined with seven modules, using a thin wire that allows precise control through a patient’s vascular system, even from kilometers away. Christie He